Literature DB >> 35854140

Knockdown of lncRNA H19 alleviates ox-LDL-induced HCAECs inflammation and injury by mediating miR-20a-5p/HDAC4 axis.

Yilin Yang1, Zhaofei Wang2, Ying Xu1, Xiaofang Liu1, Yehai Sun1, Wei Li3.   

Abstract

BACKGROUND: Coronary artery disease (CAD) seriously disturbs the life of people. LncRNA H19 is reported to promote the progression of CAD; Nevertheless, the detailed mechanism by which H19 modulates CAD development is unclear.
METHODS: Clinical samples of CAD patients were collected, meanwhile we established in vitro and in vivo models of CAD by treating HCAECs with ox-LDL and feeding ApoE-/- mice with high fat diets (HFD). MTT assay was adopted to assess the cell viability. Transwell detection was applied to test the migration, and apoptosis was tested by flow cytometry. The levels of inflammatory cytokines were examined by ELISA. The relation among H19, miR-20a-5p and HDAC4 was explored by dual luciferase reporter and RIP assay.
RESULTS: H19 and HDAC4 levels were elevated, while miR-20a-5p was reduced in plasma of CAD patients and ox-LDL-treated HCAECs. ox-LDL increased H19 level and induced apoptosis and inflammation in HCAECs, while silencing of H19 rescued this phenomenon. In addition, the level of H19 was negatively correlated with miR-20a-5p, and miR-20a-5p inhibitor restored the effect of H19 silencing on HCAECs function. HDAC4 was the downstream mRNA of miR-20a-5p, and miR-20a-5p upregulation reversed ox-LDL-induced HCAECs injury through targeting HDAC4. Furthermore, H19 silencing significantly alleviated the coronary atherosclerotic plaques and inhibited the inflammatory responses in vivo.
CONCLUSIONS: We proved that knockdown of H19 alleviated ox-LDL-induced HCAECs injury via miR-20a-5p/HDAC4 axis, which might provide a new tactics against CAD.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  CAD; H19; HDAC4; miR-20a-5p

Mesh:

Substances:

Year:  2022        PMID: 35854140     DOI: 10.1007/s00011-022-01604-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   6.986


  38 in total

1.  Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease.

Authors:  Lin Li; Laiyuan Wang; Hongfan Li; Xikun Han; Shufeng Chen; Bin Yang; Zunsong Hu; Huijuan Zhu; Can Cai; Jichun Chen; Xiangdong Li; Jianfeng Huang; Dongfeng Gu
Journal:  Atherosclerosis       Date:  2018-06-18       Impact factor: 5.162

Review 2.  LncRNA HOXA-AS2 and its molecular mechanisms in human cancer.

Authors:  Jicai Wang; Zhilei Su; Shounan Lu; Wen Fu; Zhifa Liu; Xingming Jiang; Sheng Tai
Journal:  Clin Chim Acta       Date:  2018-07-04       Impact factor: 3.786

3.  Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction.

Authors:  Christopher E Radecke; Alexandra E Warrick; Gagan D Singh; Jason H Rogers; Scott I Simon; Ehrin J Armstrong
Journal:  Thromb Haemost       Date:  2014-11-20       Impact factor: 5.249

4.  BDNF corrects NLRP3 inflammasome-induced pyroptosis and glucose metabolism reprogramming through KLF2/HK1 pathway in vascular endothelial cells.

Authors:  Hong Jin; Yi Zhu; Xiao-Dong Wang; Er-Fei Luo; Yi-Ping Li; Bi-Lei Wang; Yi-Fei Chen
Journal:  Cell Signal       Date:  2020-11-27       Impact factor: 4.315

5.  Microfluidic assay of circulating endothelial cells in coronary artery disease patients with angina pectoris.

Authors:  Shuiyu Chen; Yukun Sun; Kuang Hong Neoh; Anqi Chen; Weiju Li; Xiaorui Yang; Ray P S Han
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

6.  LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease.

Authors:  Jin Tan; Shengzhong Liu; Qin Jiang; Tao Yu; Keli Huang
Journal:  Cardiol Res Pract       Date:  2019-04-16       Impact factor: 1.866

7.  Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.

Authors:  MengYing Zeng; XiaoWei Yan; Wei Wu
Journal:  BMC Cardiovasc Disord       Date:  2021-09-17       Impact factor: 2.298

8.  The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κB signalling pathway.

Authors:  Feng Guo; Chengchun Tang; Yawei Li; Yuqing Liu; Ping Lv; Wei Wang; Yongyong Mu
Journal:  J Cell Mol Med       Date:  2018-08-05       Impact factor: 5.310

9.  LncRNA CASC11 was downregulated in coronary artery disease and inhibits transforming growth factor-β1.

Authors:  Junhua Chen; Jianli Dang
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

10.  LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6.

Authors:  Huihua Kai; Qiyong Wu; Ruohan Yin; Xiaoqiang Tang; Haifeng Shi; Tao Wang; Ming Zhang; Changjie Pan
Journal:  Front Cell Dev Biol       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.